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Background: Sulfadoxine-pyrimethamine (SP) combination drug is currently being used in India for the treatment
of Plasmodium falciparum as partner drug in artemisinin-based combination therapy (ACT). Resistance to sulfadoxine
and pyrimethamine in P. falciparum is linked with mutations in dihydropteroate synthase (pfdhps) and dihydrofolate
reductase (pfdhfr) genes respectively. This study was undertaken to estimate the prevalence of such mutations in pfdhfr
and pfdhps genes in four states of India.
Methods: Plasmodium falciparum isolates were collected from two states of India with high malaria incidence i.e.,
Jharkhand and Odisha and two states with low malaria incidence i.e., Andhra Pradesh and Uttar Pradesh between
years 2006 to 2012. Part of sulfadoxine-pyrimethamine (SP) drug resistance genes, pfdhfr and pfdhps were PCR-amplified,
sequenced and analyzed.
Results: A total of 217 confirmed P. falciparum isolates were sequenced for both Pfdhfr and pfdhps gene. Two pfdhfr
mutations 59R and 108N were most common mutations prevalent in all localities in 77 % of isolates. Additionally, I164L
was found in Odisha and Jharkhand only (4/70 and 8/84, respectively). Another mutation 51I was found in Odisha only
(3/70). The pfdhps mutations 436A, 437G, 540E and 581G were found in Jharkhand and Odisha only in 13, 26, 14 and
13 % isolates respectively, and was absent in Uttar Pradesh and Andhra Pradesh. Combined together for pfdhps and
pfdhfr locus, triple, quadruple, quintuple and sextuple mutations were present in Jharkhand and Odisha while absent in
Uttar Pradesh and Andhra Pradesh.
Conclusion: While only double mutants of pfdhfr was present in low transmission area (Uttar Pradesh and Andhra
Pradesh) with total absence of pfdhps mutants, up to sextuple mutations were present in high transmission areas
(Odisha and Jharkhand) for both the genes combined. Presence of multiple mutations in pfdhfr and pfdhps genes
linked to SP resistance in high transmission area may lead to fixation of multiple mutations in presence of high
drug pressure and high recombination rate.
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Malaria is one of the major health problems in tropical
and subtropical countries. One of the greatest challenges to
malaria treatment is the development and spread of resist-
ance in parasites especially in Plasmodium falciparum
which threaten the usable lifespan of even artemisinin-
based combination therapies, affecting both the artemisinin
component and the partner medicine [1]. India has evi-
denced resistant parasite especially P. falciparum against all
available conventional antimalarials like chloroquine (CQ)
and sulfadoxine-pyrimethamine (SP) [2]. A decade long use
of artemisinin-based combination therapy (ACT) had been
proved a hallmark anti-malarial therapy for all the malaria
endemic countries [3]. The reports of chloroquine resist-
ance in P. falciparum in early 1980s lead to introduction of
SP as a second line antimalarial drug in CQ-resistant areas
of India [4]. Sulfadoxine and pyrimethamine acts as a syner-
gistic combination and was used as long acting partner
antimalarial drug in ACT in South Asia, Middle East and
South America [3]. Since 2005, Indian antimalarial drug
policy has introduced artesunate with SP as ACT in place
of SP in high malaria endemic areas, and later in 2010, this
treatment became the recommended first line treatment
throughout India [5, 6]. Further, since 2013, prevalence of
resistant genotype of falciparum against this partner drug
SP, led to introduction of artemether-lumefantrine as anti-
malarial therapy for northeastern part of India [7, 8].
The synergistic combination of the sulfadoxine and
pyrimethamine inhibits dihydropteroate synthase (dhps)
and dihydrofolate reductase (dhfr) enzymes respectively
in the folate-pathway of parasite [9]. The development
of resistance against SP emerges with a single point mu-
tation in the parasite dhfr and dhps gene, which further
augments with stepwise addition of mutations [10–12].
Resistance to pyrimethamine is primarily conferred by a
point mutation at codon 108 and augmented by mutations
at codon 16, 51, 59 and 164 of Plasmodium falciparum dhfr
(pfdhfr) gene [10, 12, 13]. Similarly, point mutation at
codon 436 or 437 in Plasmodium falciparum dhps
(pfdhps) gene may initiate the resistance and followed
by mutations at codon 540, 581 and 613, which are
considered for augmentation of sulfadoxine resistance
[11, 13, 14].
A single mutation in pfdhfr or pfdhps gene is not
enough to cause treatment failure and multiple mutation
combinations in these two genes were associated with
failure of SP as anti-malarial therapy [15, 16]. Various
parts of India reported single, double, triple and quadruple
mutant pfdhfr gene [17–22]. However, double mutation at
codon 59 and 108 in pfdhfr gene was predominant
throughout India [17–22]. Triple mutant pfdhfr gene
indicating high level of antifolate resistance was observed
in India from northeast states, Car Nicobar island and
Odisha [7, 15, 20, 22, 23]. Highly resistant quadruplemutant allele was observed in high and low frequencies
from Car Nicobar island and northeastern parts of
India respectively [19, 20, 22, 24, 25]. Wild-type allele
in pfdhps gene was predominant in all geographic re-
gions of India except Andaman and Nicobar island,
where lower frequency of mutations in pfdhps gene was
observed in comparison to pfdhfr gene, which supports
that mutations first emerged in pfdhfr and then occurs
in pfdhps gene [23]. Single mutation at codon 437 was
observed in low frequency from Assam, Odisha, Madhya
Pradesh and Uttar Pradesh [21, 23, 26]. Further, double
and triple mutation including mutation at codon 437 was
also observed in low frequencies from Madhya Pradesh,
northeast and Odisha [20, 26, 27]. However, recent studies
from northeastern part of India showed increased number
of key mutation at codon 437 included in triple and quad-
ruple mutations in pfdhps gene [7, 20, 22].
Development of resistance against ACT is currently a
major threat and P. falciparum bearing resistance against
its partner drug (here, SP) may lead to ACT failure [3].
The reports of widespread resistance against SP generate
concern about long-term effectiveness of ACT in India [5,
20]. A recent study reported significant reduction in effi-
cacy of SP treatment from northeastern areas of India,
which is considered as a gateway for invasion of drug re-
sistant parasite from Southeast Asia to India [7, 20, 22].
Thus, routine molecular surveillance of SP resistance
markers is essential in malaria endemic regions, which will
help in formulating an effective malaria treatment strategy.
Here, we attempted to determine the changes in the
frequencies of dhfr and dhps mutations in P. falciparum
isolates from four states of India (Jharkhand, Odisha,
Andhra Pradesh and Uttar Pradesh) to assess the level
of SP resistance.
Methods
Study population and blood sample collection
Finger prick blood-spots (n = 217) were collected on
Whatman 3MM filter paper from all microscopically-
confirmed P. falciparum positive patients. This study
has been approved by the Institutional Ethics Committee
(IEC), and the Scientific Advisory Committee (SAC) of
National Institute of Malaria Research. All isolates were
collected between years 2006–2012. The study included
patients with symptoms of uncomplicated malaria, visiting
Primary Health Centre (PHC) situated in the six districts
of the four different states of India, i.e., Jharkhand, Odisha,
Andhra Pradesh and Uttar Pradesh which are described
below. Artemesinin-based combination therapy was
implemented as the first line of antimalarials drug for
treatment of P. falciparum in some districts of Andhra
Pradesh, Jharkhand and Orissa since 2008 and in Uttar
Pradesh since 2010. Samples were collected from fol-
lowing sites:
Table 1 List of primers used in the study
Name of
primers
Sequence (5’- 3’) Expected size References
AMP-1 F TTTATATTTTCTCCTTTTTA 720 bp [18]
AMP-2R CATTTTATTATTCGTTTTCT
M1 TTTATGATGGAACAAGTCTGC 648 bp [38]
M5 AGTATATACATCGCTAACAGA
M3717F CCATTCCTCATGTGTATACAACAC 1287 bp [18]
186R GTTTAATCACATGTTTGCACTTTC
Rc GGTATTTTTGTTGAACCTAAACG 728 bp [38]
Rd ATCCAATTGTGTGATTTGTCCAC
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samples were collected from villages under PHC
Tamar, district Ranchi (23° 23' N latitude and 85° 23'
E longitude) and East Singhbhum PHC (23° 01' N
latitude and 86° 54' E longitude). The Annual
Parasite Incidence (API, i.e., ‰ malaria case in a
year) of Jharkhand is ≥5 [28, 29]. Samples (n = 84)
were collected between year 2006 and 2011 during
which proportion of P. falciparum malaria has
increased from 24 % (n = 48388) to 44 % (n = 70302)
in Jharkhand state [30].
2. Odisha: Samples were collected from villages under
Rayagada PHC (19° 09' N latitude and 83° 27' E
longitude) and Rourkela PHC (22° 25' N latitude and
85° 00' E longitude) of Odisha state are belonging to
hyper endemic areas show a higher level of drug
resistance and intense perennial malaria transmission.
API of Odisha is ≥5 [28, 29]. Odisha alone contributed
approximately 25 % of the total malaria cases and
45 % of total falciparum malaria cases reported in the
country during recent years (2008–2012). All isolates
(n = 70) collected from this site between years 2008,
2010–2012 during which proportion of P. falciparum
malaria increased from 87 % (n = 329631) to 93 %
(n = 244503) [30].
3. Andhra Pradesh: Samples were collected from PHC
Salur, district Vizianagaram (18° 53' N latitude and
83° 21' E longitude) which is located in the northern
part of the Godavari district which is dominated by
tribal populations. Malaria endemicity is low, with
annual transmission and API of Andhra Pradesh
is ≥2 [29]. Samples (n = 32) were collection from this
site during year 2011. During this period, P. falciparum
was the predominant malaria spices in Andhra Pradesh
and accounting for 70 % (n = 24089) of total reported
malaria infection [30].
4. Uttar Pradesh: Samples were collected from PHC
Razapur, district Ghaziabad (28° 40' N latitude and
77° 28' E longitude). Ghaziabad is an industrial area,
located in between three river named Hindon, Ganga
and Yamuna. Malaria endemicity is low with seasonal
transmission and P. vivax is the predominant malaria
species in this region. API of Ghaziabad is ≥2 [29].
Sample (n = 31) were collected from this site during
years 2011 and 2012; during that time only 3.25 %
(n = 1857) and 1.56 % (n = 740) of total malaria
burden was attributed to P. falciparum in same
years respectively [30].
DNA isolation and molecular diagnosis
Genomic DNA was extracted from dried filter paper
blood spots using QIAmp Blood mini kit (Qiagen, Krefeld,
Germany) as per the manufacture’s instruction. A PCR
diagnosis was performed to confirm the presence of P.falciparum infection and rule out any mixed species in-
fection as described earlier [31].
SNP’s genotyping in pfdhfr and pfdhps genes
PCR amplification of pfdhfr gene
A 720 base pair fragment of pfdhfr gene was amplified
as described earlier [18] and nested PCR was performed
to amplify 648-bp fragment covering various single nu-
cleotide polymorphism (SNP) A16V, N51I, C59R, S108N
and I164L correlated with pyrimethamine resistance.
Primary PCR (25 μL) reaction contained 4 μl DNA tem-
plate, 200 μM of dNTPs, 1x PCR buffer, 0.30 μM of primers
AMP-1 F and AMP-2R, and 2.5 U Taq polymerase (Sigma,
India). The cycling parameters used were as follows: an
initial denaturation at 94 °C for 3 min, denaturation at
94 °C for 30 s, annealing at 45 °C for 45 s, and extension
at 72 °C for 45 s, for 45 cycles followed by an extension
step at 72 °C for 5 min. Nested PCR was performed using
2.5 μl templates from first round PCR product, 0.30 μM of
primers M1 and M5, 200 μM of each dNTP, 1x PCR buf-
fer, and 1 U of Taq polymerase in a 25 μl reaction. The
PCR was carried at 94 °C for 3 min, followed by 35 cycles
at 94 °C for 1 min, 45 °C for 1 min, 72 °C for 1 min and fi-
nally 72 °C for 10 min. The PCR amplicon was visualized
in 2 % Agarose gel. The list of primers used for PCR-
amplification is provided in Table 1.
PCR amplification of pfdhps gene
A nested PCR assay was performed to amplify 728-bp
fragment of the pfdhps gene covering SNP’s S436A, A437G,
K540E, A581G and A613S known to be associated with
sulfadoxine resistance as described earlier [18]. Primary
PCR reaction of 25 μL was prepared consisting 4 μl DNA
template, 200 μM of each dNTP, 1x PCR buffer, 0.30 μM of
primers M3717F and 186R and 2.5 U Taq polymerase
(Sigma, India). The cycling parameters used were as
follows: an initial denaturation at 94 °C for 5 min, de-
naturation at 94 °C for 30 s, annealing at 55 °C for 45 s,
and extension at 72 °C for 90 s, for 45 cycles followed
by an extension step at 72 °C for 10 min. Nested PCR
Sharma et al. Parasites & Vectors  (2015) 8:471 Page 4 of 9was performed using 2.5 μl templates from first round
PCR product, 0.30 μM forward primer (Rc) and
0.50 μM reverse primer (Rd), 200 μM of each dNTP, 1x
PCR buffer, and 1 U of Taq in a 25 μl reaction. The
PCR was carried at 94 °C for 4 min, followed by 30 cycles
at 94 °C for 30 s, 50 °C for 40 s, 72 °C for 1 min and finally
72 °C for 10 min. The PCR amplicon was visualized in
2 % Agarose gel. The list of primers used for PCR-
amplification is provided in Table 1.DNA sequencing and analysis
All successful nested PCR amplicons were purified using
MinElute PCR Purification Kit (Qiagen, Krefeld, Germany)
and subjected to DNA sequencing using Big-Dye Termin-
ator Kit version 3.1 (Applied Biosystems, Foster, USA).
Sequencing was performed on both strand of DNA to
confirm SNP's. The chromatogram was manually edited
in Finch TV and mixed bases were carefully scored. Se-
quences obtained were aligned in software MEGA version
5 [32] using ClustalW implemented in the program with
the wild type sequence obtained from GenBank with Ac-
cession number J03028.1 and PFU07706 for pfdhfr and
pfdhps respectively. DNA sequences obtained were submit-
ted to GenBank (accession numbers KP30040 – KP300256
for pfdhfr and KP300257 – KP300473 for pfdhps gene).
The genetic diversity parameters such as haplotype diversity
and two measures of nucleotide diversity; θw and π were es-
timated in software DnaSP version 5.10.01. The estimation
of θw and π is based on the number of segregating sites and
mean number of pairwise nucleotide differences respect-
ively. To test the neutrality in molecular evolution of pfdhfr
and pfdhps gene, Tajima's D was calculated based on the
normalized discrepancy between θw and π. Other measures
of neutrality such as Fu and Li's D* and Fu and Li's F* were
also evaluated.Table 2 Regional distribution of pfdhfr mutations
pfdhfr genotypes
State N N51I C59R
N I N + I C R
High transmission areas
Jharkhand 84 84 - - 8 46














32 32 - - 17 8
Uttar
Pradesh
31 31 - - 4 23
Total 63 63 (100 %) - - 21
(33.3 %)
31
(49.2 %)Sulfadoxine-Pyrimethamine resistance genotypes
Mutations at both genes were concatenated to form
combined mutant genotypes, which in turn provide in-
formation about various levels of clinical resistance to
SP treatment. In an earlier study [18], the combined
mutant genotypes were categorized for following types of
clinical resistance; category "S/RI" with single or double
mutation in combined genotype infers early emergence of
SP resistance; category "RI" with triple mutation in com-
bined genotype suggests low level of SP-resistance; cat-
egory "RI/RII" with triple mutation in pfdhfr gene suggests
initiation of high level SP-resistance; category "RII/RIII"
with quintuple mutations in combined genotype suggests
higher level of SP-resistance; category "RIII" with sextuple
mutations in combined genotype suggests total failure of
SP treatment.
Results
Mutation analysis of pfdhfr and pfdhps genes
All 217 isolates were successfully sequenced for pfdhfr and
pfdhps genes covering codon positions 16, 51, 59,108 and
164 of pfdhfr gene and codons 436, 437,540,581 and 613
of pfdhps gene. The distribution of amino acid substitution
at various codon positions for pfdhfr and pfdhps genes are
shown in Tables 2 and 3 respectively In total, sequencing
results showed pure alleles at all the codons in n = 38
(17.51 %) isolates. No mutant alleles were detected at codon
16 in pfdhfr gene and at codon 613 in pfdhps gene. In
pfdhfr gene, majority of isolates were observed with pure
mutant alleles 59R (n = 117, 54 %) and 108N (n = 139,
64 %) and mixed mutant allele 59R* was observed in
23.04 % (n = 50) and 108N* in 18.43 % (n = 40) isolates.
However, pure mutant alleles 51I (n = 2, 0.92 %) and 164 L
(n = 7, 3.22 %) were less prominent at codons 51 and 164
respectively. Mixed mutant alleles were observed in 0.46 %
(n = 1) and 2.30 % (n = 5) at codon 51 and 164 respectively.S108N I164L
C + R S N S + N I L I + L
30 3 55 26 76 4 4
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Table 3 Regional distribution of pfdhps mutations
State N pfdhps genotypes
S436A A437G K540E A581G
S A S + A A G A + G K E K + E A G A + G
High transmission areas
Jharkhand 84 76 6 2 55 25 4 76 6 2 64 17 3
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has been provided in supplementary Additional file 1: Ta-
bles S1. The haplotype diversity (Hd) = 0.611 was estimated
in pfdhfr gene with variance of haplotype diversity: 0.00081
and standard deviation of haplotype diversity: 0.028. The
nucleotide diversity per site estimated was Pi = 0.00183,
with sampling variance of Pi: 0.0000005 and standard
deviation of Pi: 0.00067. The average number of nu-
cleotide differences was k = 0.920,theta (per sequence)
from S, Theta-W = 0.668 and theta (per site) from S,
Theta-W= 0.00133.For dhfr gene analysis Tajima's D was
0.65908 (Not significant, P > 0.10). Fu and Li's D* test and
Fu and Li's F* test statistic also showed not significant at
P > 0.10 with a value of 0.87589 and 0.95422 respectively.
The value of Fu’s Fs statistic = 0.001 and Strobeck’s S
statistic = 0.685.
While in pfdhps gene, wild-type alleles were predominant
(79.26 %, n = 172) at all the codons (Table 2). Pure mutant
alleles were observed in 7.37 (n = 16), 16.58 (n = 36), 7.83
(n = 17) and 7.83 % (n = 17) at codons 436, 437, 540 and
581 respectively. However, mixed mutant alleles were also
prevailed in 1.84, 2.30, 2.30 and 1.38 % at codons 436,
437, 540 and 581 respectively. Year-wise breakup of
pfdhps mutations in different sites has been provided in
supplementary Additional file 2: Tables S2. The haplotype
diversity Hd = 0.335 was estimated in pfdhps gene with
variance of haplotype diversity = 0.00161 and standard de-
viation of haplotype diversity = 0.040.The nucleotide diver-
sity per site estimated was Pi = 0.00133, sampling variance
of Pi = 0.0000004and standard deviation of Pi = 0.00059.
The average number of nucleotide differences was k =
0.756, theta (per sequence) from S, Theta-W = 0.673 and
theta (per site) from S, Theta-W = 0.00118. For dhps gene
analysis Tajima's D was 0.21856 (Not significant, P > 0.10).
The Fu and Li's D* test statistic = 0.87896 and Fu and
Li's F* test statistic = 0.78220 were also not statisticalsignificant (P > 0.10). The Fu's Fs statistic = −2.372 and
Strobeck’s S statistic = 0.965
Mutant genotype status of pfdhfr and pfdhps genes
In pfdhfr gene, pure wild genotype ANCSI was found in
17.51 % (n = 38) isolates. Prevalence of single mutant
(ANCNI), double mutant (ANRNI) genotypes were ob-
served in 2.76 (n = 6) and 46.08 % (n = 100) isolates while
mixed single mutant genotype (ANCN*I) and mixed
double mutant genotypes (ANR*N*I) were observed in
2.76 (n = 6) and 23.50 % (n = 51) isolates respectively. Pure
triple mutant genotypes were two type ANRNL (3.22) and
AIRNI (0.92 %) while mixed triple mutant genotypes
ANRNL* (2.30) and AI*RNI (0.46 %). No quadruple
mutant genotypes were found in pfdhfr gene.
In case of pfdhps gene, majority of isolates (79.26 %)
were found pure wild genotype SAKAA. SGKAA (1.84 %),
AAKAA (0.46 %) and SAEAA genotype (0.46 %) are
different pure single mutant genotypes, while SAE*AA
(0.92 %) is mixed single mutant genotype. Prevalence
of pure double mutant genotype (SGKGA) and triple
mutant genotype (AGEAA) were (7.83) and (6.91 %)
respectively, while mixed double mutant (SG*KG*A)
and triple mutant (A*GEAA) were (0.92) and (1.38 %)
respectively. Only one isolate showed mixed quadruple
mutant genotype i.e. A*GEGA.
Two-locus mutation status of pfdhfr and pfdhps genes
A total of 13 different pfdhfr-pfdhps two locus genotypes
were observed among 217 isolates which are presented
in Table 4. Wild-type two locus genotypes were observed
in 17.51 % (n = 38) isolates. Mutant two locus genotypes
were observed in 82.48 % (n = 179) isolates. Out of that,
62.6 % (n = 136) isolates showed mutant pfdhfr in the
two-locus combination. The majority of isolates (115 of
136) had double mutant pfdhfr (GEN3) while single and

















GEN 1 ANCSI-SAKAA S 3 (3.57) 21 (30.00) 14 (43.75) 38 (17.51)
Mutant
genotypes
GEN 2 ANCNaI-SAKAA S/RI 4 (4.76) 1 (1.43) 3 (9.38) 4 (12.90) 12 (5.53)
GEN 3 ANRaNaI-SAKAA S/RI 45 (53.57) 28 (41.43) 15 (46.88) 27 (87.10) 115 (52.99)
GEN 4 ANRNI-SGKAA RI 1 (1.19) 1 (1.43) 2 (0.92)
GEN 5 ANRaNI-AAKAA RI 1 (1.43) 1 (0.46)
GEN 6 ANRaNaI-SAEaAA RI 2 (2.86) 2 (0.92)
GEN 7 AIaRNI-SAKAA RI/RII 3 (4.29) 3 (1.38)
GEN 8 ANRNLa-SAKAA RII 4 (4.76) 2 (2.86) 6 (2.76)
GEN 9 ANRaNaI-SGaKGaA RII 18 (21.42) 18(8.29)
GEN 10 ANRNL-SGaKGaA RII 1 (1.19) 1 (0.46)
GEN 11 ANRNI-AaGEAA RII/RIII 4 (4.76) 8 (11.42) 12 (5.52)
GEN 12 ANRaNaI-AaGaEaGaA RIII 1 (1.19) 1 (0.46)
GEN 13 ANRaNaLa-AaGaEaAA RIII 3 (3.57) 3 (4.29) 6 (2.76)
amixed (wild +mutant)
bresistance level classified as per Ahmed et al. [18]
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(GEN7 and GEN8 ) isolates respectively. Mutant genotype
for both genes in the two locus combination was observed
in 19.81 % (n = 43) isolates. The two locus combined mu-
tant genotypes were categorized into various levels of clin-
ical resistance as described earlier [18], which was based
on number of mutations observed in the combination
(Table 4). The category "S/RI" representing emergence of
SP resistance was observed as genotype GEN2 and GEN3
in 58.52 % (n = 127) isolates. The category "RI" suggested
low level of resistance against SP treatment was observed
as genotype GEN4-6 in 2.30 % (n = 5) isolates. The cat-
egory "RI/RII" suggested for high level of resistance against
SP treatment was observed as genotype GEN7 in 1.38 %
(n = 3) isolates. The category "RII" with quadruple muta-
tion in two locus combination suggested for higher level
of resistance against SP treatment was observed as geno-
type GEN8-10 in 11.52 % (n = 25) isolates. The category
"RII/RIII" with quintuple mutation in two-locus combin-
ation also suggested for higher level of resistance against
SP treatment was observed as genotype GEN11 in 5.53 %
(n = 12) isolates. The category "RIII" with sextuple muta-
tion in two locus combination suggested for level of resist-
ance that can lead to total failure against SP treatment was
observed as genotype GEN12-13 in 3.22 % (n = 7) isolates.
Spatial distribution of mutations in pfdhfr and pfdhps genes
The wild-type ANCSI was observed at all study sites
except Uttar Pradesh. Double mutant ANRNI allele inpfdhfr gene was prevalent in all four states Uttar Pra-
desh (87 %, n = 31), Jharkhand (83.33 %, n = 84), Odisha
(57.14, n = 70) and Andhra Pradesh (46.87 %, n = 32).
Triple mutants ANRNL and AIRNI allele was observed
in (5.71, n = 70) and (4.28 %, n = 70) isolates respect-
ively at Odisha. Isolates from Jharkhand also showed
ANRNL in (9.52 %, n = 84) isolates. Thus mutation
164L associated with higher level of drug resistance
was present among isolates from Jharkhand (9.52) and
Odisha (5.71 %), which are high transmission regions
but not detected in Uttar Pradesh and Andhra Pradesh
isolates. Mutation at codon 51 occurred rarely at Odi-
sha (n = 3).
The wild-type SAKAA in pfdhps gene was prevalent at
Jharkhand (65.47 %, n = 55) and Odisha (77.14 %, n = 54).
No mutant pfdhps gene was observed at Andhra Pradesh
and Uttar Pradesh. Single key mutation at position 437
(i.e. SGKAA) occurred rarely at Jharkhand (n = 2). While
Odisha showed single mutant alleles at different positions
which were at codon 436 (i.e. AAKAA, n = 1) at key codon
437 (i.e. SGKAA, n = 1) and at codon 540 (i.e. SAEAA,
n = 2). Mutation at codon position 581 was existed only
in Jharkhand isolates with prevalence 23.80 % (n = 20).
Double mutant allele SGKGA (23.80 %, n = 84) was
observed only in Jharkhand isolates. Thus, Jharkhand
and Odisha isolates showed mutations at all codons
but with a varied rate. Triple mutant allele AGEAA
was observed in isolates from Odisha (15.71 %, n = 70)
and Jharkhand (8.33 %, n = 84). Only one isolates from
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i.e. AGEGA. No isolate was found to contain S436F
and A613S/T mutations.
Uttar Pradesh and Andhra Pradesh showed the two-
locus genotype GEN1 categorized as susceptible "S" and
genotype GEN2-3 categorized as "S/RI" only. Whereas,
Jharkhand and Odisha showed various genotypes catego-
rized for susceptible (S), emerging resistance (S/RI, RI)
and also high resistance (RII, RIII). In Jharkhand isolates,
double mutant genotype (GEN3) was most prevalent in
53.57 % isolates, whereas the prevalence of triple mutant
(GEN4, 8) and quadruple mutant (GEN9) genotypes were
5.95 and 21.42 % respectively. Highly resistant quintuple
mutant genotype (GEN10-11) and sextuple mutant geno-
type (GEN12-13) were observed in five and four isolates
respectively. In Odisha 30 % isolates showed wild-type
genotype (GEN1). Like Jharkhand, Odisha also showed
prevalence of double mutant genotype (GEN3) i.e. 41.43 %
as compared to other mutant genotype. Prevalence of
triple (GEN4-8), quintuple (GEN11) and sextuple mu-
tant genotype (GEN12-13) was 12.85, 11.43 and 4.29 %
respectively. Quadruple mutant genotype was absent in
Odisha.
Discussion
Currently, combination of fast and long acting antimalarial
drugs is recommended as an ideal approach over the use
of single antimalarial drug [3]. Optimizing the choice of
long acting partner antimalarial drug in ACT is important
challenge to be addressed in successful malaria treatment
programme [33]. Presence of resistant parasites against
the long acting antimalarial used in ACT can hamper the
treatment efficacy and can also lead to emergence of arte-
misinin resistant parasite [7]. All malaria endemic parts of
India experienced mutant parasites conferring resistance
to all conventional antimalarial drugs like CQ, SP and thus
there was country wide adoption of AS + SP as ACT in
year 2010 [5]. However, resistance to SP had been well
documented from northeastern part of India, which led to
use of AS + lumefantrine as first-line malaria treatment in
these parts of country since year 2013[7]. Northeast region
of India has already been documented as important route
for invasion of parasite bearing resistant genotypes against
many antimalarials and proved its potential to be a focus
for spread of resistant parasite to other parts of country
[20]. Thus, monitoring of mutation status of partner SP is
important for better management of antimalarial policy.
Here, mutation status of pfdhfr and pfdhps gene respon-
sible for resistance against SP was evaluated for isolates
from four different geographic areas.
The study showed 17.51 wild-type pfdhfr gene and
79.26 % wild-type pfdhps gene. Higher number of mutant
pfdhfr gene was observed in comparison to pfdhps gene
at all the study sites infer development of mutationsoccurred first in pfdhfr gene and then in pfdhps gene
under selective drug (SP) pressure. The prevalence of
double mutant (ANRNI) in pfdhfr gene and wild-type
pfdhps gene at all the study sites corroborated earlier
reports of predominant presence for the same [23].
However, single mutant ANCNI, triple mutants (ANRNL
or AIRNI) in pfdhfr gene and single mutants (SGKAA,
AAKAA and SAEAA), double mutant SGKGA, triple
mutant AGEAA, quadruple mutant AGEGA were also
observed. Single or double pfdhfr mutations alone cannot
cause SP treatment failure but the double pfdhfr mutations
with a single or more mutation in pfdhps gene can cause
various level of SP resistance [15]. In addition, triple mu-
tant pfdhfr alone can cause various level of SP resistance.
The DHFR-DHPS two locus mutations have importance
to monitor as it can infer the clinical susceptibility of SP
[15, 18]. This study observed 13 such two locus genotypes
(GEN 1–13) within 217 isolates (Table 4). Out of all
isolates, only 17.51 % were wild-type (GEN1). In total,
double mutant genotype (GEN3) was observed in 52.99 %
isolates and its predominance indicates continuous emer-
gence of SP resistance in all study sites. The study sites in-
clude both high malaria transmission area (Odisha and
Jharkhand) and low malaria transmission areas (Andhra
Pradesh and Uttar Pradesh). Triple mutant genotype
(GEN 4–8) that can confer high SP resistance were ob-
served in Odisha and Jharkhand with prevalence of 12.85
and 5.95 % respectively, while quadruple mutant (GEN9)
was found only in Jharkhand with 21.42 % prevalence. Iso-
lates from high transmission areas also showed quintuple
(Jharkhand = 5.95 %, Odisha = 11.43 %) and sextuple
(Jharkhand = 4.76 %, Odisha = 4.29 %) mutant genotype.
Quintuple and sextuple mutant genotypes associated with
higher level of resistance to SP suggests selective drug
pressure due to its use since a long period. Here, high
transmission areas showed higher number of mixed
mutations (both wild and mutant alleles) in both pfdhfr
and pfdhps genes, which were possibly due to multi-clonal
infection, as high recombination event is expected here,
which in turn adding allelic variation. High genetic diver-
sity at these high transmission areas in both gene under
selection and neutral microsatellite markers were reported
when compared to low transmission region of India
[34, 35]. Higher genetic diversity and more fixation
probability in genes responsible for various antimalarial
resistance was observed earlier and suggested the role of
malaria transmission intensity and drug exposure [36, 37].
The mutations 164L in pfdhfr and 437G and 540E muta-
tions in pfdhps gene were reported to be responsible for
therapeutic failure of SP [20, 22], and the same were
observed in 9.52 and 34.52 % respectively in Jharkhand.
In Odisha 4.28 % isolates showed another mutation 51I
in pfdhfr gene which was responsible to accelerate the
SP-resistance [15, 16]. In addition, these mutations are
Sharma et al. Parasites & Vectors  (2015) 8:471 Page 8 of 9also part of two-locus genotypes (GEN 7–13) would be
involved in clinical resistance against SP. In pfdhps gene,
triple mutant AGEAA was found in 15.71 % of Odisha iso-
lates, while double mutant SGKGA is found only in
23.80 % of Jharkhand isolates. The prevalence of mutants
found here in high transmission areas are similar to re-
ported earlier from northeastern region [20, 22], however
the prevalence of mutant two locus genotypes were not
similar. Mutations like S436F, A613T/S was not observed
in this study.
In contrast, the low transmission areas (Uttar Pradesh
and Andhra Pradesh) showed single mutation (11.11 %)
at codon positions 108, double mutations (66.67 %) at
codon positions 59 and 108 in pfdhfr gene, while no iso-
late showed the N51I and I164L mutations associated
with SP treatment failure. Thus the triple and quadruple
mutations were not observed in pfdhfr gene. In case of
pfdhps all isolates were wild-types, which infers P. falcip-
arum population in these regions were susceptible to SP
treatment and resistance could be in developing state.
The low transmission areas showed mutations similar to
earlier reports of similar single and double mutations
from Uttar Pradesh and Delhi in year 2001, which sug-
gested higher susceptibility for SP was maintained due to
higher clonal populations in these regions [18]. In addition,
P. vivax is prevalent in Uttar Pradesh and chloroquine is
still effectively used as antimalarial treatment against P.
vivax in India, which could provide selection pressure on
gene responsible for chloroquine resistance in P. falciparum
[34]. Thus no or low selection pressure of antifolate drugs
in P. falciparum was predicted in these P. vivax prevalent
areas as misdiagnosed of mixed infection cases was
more exposed to chloroquine in comparison to antifo-
late drug .Conclusion
In conclusion, the present findings suggest that SP can be
effective for the treatment of uncomplicated falciparum
malaria as a partner drug of ACT in Andhra Pradesh
and Uttar Pradesh (low transmission areas). In Jharkhand
and Odisha (high transmission area), results suggest
that mutation rate will increase continuously due to
continued drug pressure and malaria transmission, which
in turn will lead to SP treatment failure in near future, as
reported in northeastern parts of India. Continuous
molecular surveillance of partner drug (SP) in these high
transmission areas is required to maintain an effective
drug policy.Additional files
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